- Filing of certain prospectuses and communications in connection with business combination transactions (425)
09 7월 2010 - 5:06AM
Edgar (US Regulatory)
Filed by Celgene Corporation
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934
Subject Company: Abraxis BioScience, Inc.
Commission File No.: 001-33657
The following document represents an excerpt from an internal publication of Celgene
Corporate Communications that was distributed to employees of Celgene Corporation, or Celgene,
related to the announcement by Celgene of its proposed acquisition of Abraxis BioScience, Inc..
Hppnp
Tuesday July 6, 2010
The Morning Notes
A New Chapter Set to Begin for Celgene
Abraxis Acquisition is an Exceptional Strategic Fit
Expanded pipeline, targeted therapeutics and solid-tumor therapies, create expansive opportunities
A major
milestone was realized last week when
Bob Hugin,
Celgene CEO, announced that Celgene had signed an
agreement to acquire Abraxis Bio-Science, a
California-based biotechnology company headquartered in
Los Angeles.
For the team members throughout Celgene, news of this
major transaction has created a greater level of
enthusiasm, evident by the reactions in Celgene offices
worldwide. Along with this, and following the closing of
the acquisition and integration of Abraxis technologies
and products, we will be afforded new opportunities to
help even more patients through an expanded portfolio of
treatment options. Of particular note will be our ability
to immediately addressfor the first timethe
solid-tumor segment of the oncology market.
Through leveraging our existing capabilities and
expertise in hematology and oncology we can help advance
commercialization efforts to provide patients these much
needed therapies. Through this acquisition, we are
advancing our global strategy and making important
strides toward critical work in the field of oncology,
becoming a world leader in the discovery and development
of novel approaches to rare and debilitating diseases.
About Abraxis...
Values, Mission, Complement and Support Celgene Strategic Plan
Sharing a similar philosophy and commitment of improving the lives of patients around the
world helps make the Abraxis BioScience acquisition an ideal fit. Through this new synergyand in
alignment with our goals and missionwe will be afforded a greater opportunity to alter the
course of diseases through the use of cutting-edge, next-generation therapies. By combining
resources and technologies, a unified Celgene can further advance its efforts to shift the
paradigm of treatment for patients, offering new therapeutic options, targeted on an expanded
product portfolio.
In addition to its headquarters location in Los Angeles, California, Abraxis BioScience also has
other locations in the United States, Canada and China. U.S. locations include: Phoenix, Arizona;
Chicago, Illinois; Durham, North Carolina, and Bridgewater, New Jersey. Richmond Hill, Ontario,
is the location of the Canadian office. And, the Switzerland location is in Barbengo; and,
Beijing is home to the location in China.
The Abraxis product pipeline includes more than five clinical oncology product
candidates in various stages of testing and development. At the center of its solid-tumor focus is
Abraxane
®
, a therapeutic compound launched in 2005, and based on its proprietary tumor targeted
technology, nab technology platform. Abraxane currently is marketed in the United States for the
treatment of metastatic breast cancer.
(continued to page 4)
|
Abraxis
BioScience
(Abraxane*
Page 2
Toesday.Jnly6.2010 The Morning NoteS
(continued from page 1)
§
Current Abraxis Locations
Richmond Hill, London
f
UK
0 nte rio. Ca nada Barbengo,
los
Anaelw, CA
Cdgene
Abraxis BioScience Pipeline
Regulatory
Filing &
Preclinical
_____
PHASE I PHASE II
PHASE III
_____
Approval
ABRAXANE
®
Breast (Metastatic)
Lung (Advanced)
Metastatic Melanoma
Pancreatic (Advanced)
ABI-008(na0
®
-docetaxel)
Prostate (Hormone Refractory)
ABI-009 (nitf^-rapamycin)
mTOR Inhibitor-Solid Tumors
ABI-011(1)31^-5 404)
Vascular Disrupting Agent -Solid Tumors
ABI-013(nail^-CY196)
ABI-010 (ns^-17AAG)
HspSO Inhibitor-Solid Tumors
Current Abraxis product Pipeline
(continued on page 5)
The Morning Notes is a publication of Celgene Corporate Communications; it is
confidential and for internal use only by Celgene Employees.
|
Page 3
Toesday.Jnly6.2010 The Morning Notes
(continued from page 4)
VAbraxis
Albumin shell
- Paclilaxel
Abraxjs
(continued on page 6)
The Morning Notes is a publication of Celgene Corporate Communications; it is confidential
and for internal use only by Celgene Employees.
|
Page 4
Toesday.Jnly6.2010 The Morninig Notes
(continued from page S)
fCdgene
Emerging Solid Tumor Pipeline: 2015
Regulatory
Filing &
Preclinical
_____
PHASE I
_____
PHASE II
_____
PHASE III
_____
Approval
ABRAXANE
_____
Breast (Metastatic)
Lung (Advanced)
Malignant Melanoma
Pancreatic (Advanced)
AMRUBICIN
_____
SCLC
b;
REVLIMID
®
Solid Tumors
Prostate Cancer
Colorectal Cancer
Renal Cell Carcinoma
ACE-011 CIA in Breast Cancer
ABI-OOBfnaffMocetaiel)
0)
Prostate (Hormone Refractory)
ABI-009 (naib^-rapamycin)
mTOR Inhibitor-Solid Tumors
ABI-011(na^94D4)
Vasular Disrupting
Agent -Solid
Tumors
ABI-013(natScY196)
ABM)10(natfM7AAG)
Hsp90 Inhibitor-Solid Tumors
(rdeene
Significant Potential: 2015 & Beyond
Celgene Expanding Pipeline
-Abraxane* Hematoi
ogy
Reylimid Hematology, l&lbi-axane
Apremilas
Pomalidomide
/isifioAX
Abraxane
Pomalidomide
Hematology
_____
Hematology
Apremilast
hthalomd
Amrubicin
Hsmatology
ACE
.
011
THALOMID
JNKCC-930
Amrubicin
_____
PDA-001
Amrubicin
Amrubicin
_____
PDA-001
GI4000
2010 2015 2020
(continued on page 7)
The Morning Notes is a publication of Celgene Corporate
Communications; it is confidential and for internal use only by Celgene Employees.
|
Pages
Tuesday.Jnly6.2010
the
Morning Notes
(continued from page 6)
About the Acquisition ...
Wall Street Responds
Positively to New Deal
Market Nods on Good News
celger
Company
Update
_____
BUY
Equity
United Slate 3ia:irHlagy
10 july
2010
celg buys abll- good fit
Banhof America Merrill Lynch
Rachel MeMiiwi +1 41567635(9
Rew9rch*fiJy5t
ML^FSS
HcheLiriEmhiifiliairl.cDni
Masha Chapman +14156763575
FtaeadiAn^Et
ABII deal fits with CELG s strategic goals
CELG yesterday announced
plans to acquire ABII.
primarily for Abraxarie
iwhich la
b
chemotherapy approved
for metsstatic breast
cancer with 20D9 sales of
S315M. The deal fits with
CELGsgoal of delivering
25% bottom line growth over
the next
J.P. Morgan Celgene
Celgene to AoquirE Abraxis:
Accelerates Expansion into
Solid Tumors- ALERT
Chj inrtfliini, Cd^rtc
Jlrfi.4Jlh.ihJ ll li*> .nl
iii A ,-iiiiMi . IN.I...-I
MftMfmiiiiih
rx
^piiuiuH
Id.
Celgene
(nasdaq: celg;
53.2-4)
Abraxis Acquisition Makes Strategic
Sense; Good Entry
into Solid Tumors
Outperform
Celgene Coiporatioii
Positive on the Abr-axis ADqukftion; Entry Into
Solid-Tumor Market for a Reasonable Price
Biotechnology Research
June 30,2010
Celgene Corporation (CELG)
oHEM
(CELG)
We Like Abraxis Deal
Company
30 June 2010 | 8 page
Celgene Corp (CELG)
Abraxis Deal is Solid Step to Building Lang-Term Value
The Morning Notes is a publication of Celgene Corporate Communications; it is confidential and for internal use only by Celgene Employees.
|
Abraxis Bioscience Inc. (MM) (NASDAQ:ABII)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Abraxis Bioscience Inc. (MM) (NASDAQ:ABII)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Abraxis Bioscience Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More News Articles